Twenty-nine studies have reported that the frequency of MYD88 L265P mutation in 2285 DLBCL patients except for central nervous system (CNS) and testicular lymphomas was 16.5% (95% CI: 11.9–22.6%)2, 3, 6, 7, 9–11, 13, 16–22, 24, 25, 27, 28, 30, 31, 33–39, 41. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.